187 related articles for article (PubMed ID: 35297216)
1. Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
Liu R; Wu Y; Gong J; Zhao R; Li L; Wan Q; Lian N; Shen X; Xia L; Shen Y; Xiao H; Wu X; Chen Y; Cen Y; Xu X
Cancer Med; 2022 Aug; 11(16):3093-3105. PubMed ID: 35297216
[TBL] [Abstract][Full Text] [Related]
2. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
Tang J; Zhao R; Zheng X; Xu L; Wang Y; Feng L; Ren S; Wang P; Zhang M; Xu M
Medicine (Baltimore); 2018 Jul; 97(29):e11400. PubMed ID: 30024511
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
Bang YH; Ryu MH; Kim HD; Lee HE; Kang YK
Int J Cancer; 2022 Nov; 151(10):1770-1777. PubMed ID: 35678337
[TBL] [Abstract][Full Text] [Related]
5. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
Qianyi W; Mei X; Rui Z; Yong W; Yutao W; Xiaoding S; Xiaoting W
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1493-1500. PubMed ID: 34319443
[TBL] [Abstract][Full Text] [Related]
6. Developed and validated a prognostic nomogram for recurrence-free survival after complete surgical resection of local primary gastrointestinal stromal tumors based on deep learning.
Chen T; Liu S; Li Y; Feng X; Xiong W; Zhao X; Yang Y; Zhang C; Hu Y; Chen H; Lin T; Zhao M; Liu H; Yu J; Xu Y; Zhang Y; Li G
EBioMedicine; 2019 Jan; 39():272-279. PubMed ID: 30587460
[TBL] [Abstract][Full Text] [Related]
7. Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features.
Wang FH; Zheng HL; Li JT; Li P; Zheng CH; Chen QY; Huang CM; Xie JW
Radiol Med; 2022 Oct; 127(10):1085-1097. PubMed ID: 36057930
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
[TBL] [Abstract][Full Text] [Related]
9. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
10. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
[TBL] [Abstract][Full Text] [Related]
11. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor.
Ran P; Tan T; Zhou H; Li J; Yang H; Li J; Zhang J
J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983680
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Gold's nomogram for predicting recurrence-free survival in gastrointestinal stromal tumors in Indian patients.
Valappil FK; Rajan R; Natesh B; Sindhu RS; Raviram S; Mathew J
Indian J Gastroenterol; 2016 May; 35(3):225-8. PubMed ID: 27256432
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.
Kang S; Ryu MH; Bang YH; Kim HD; Lee HE; Kang YK
Cancer Res Treat; 2022 Oct; 54(4):1167-1174. PubMed ID: 34883555
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prognostic prediction models for rectal gastrointestinal stromal tumor.
Jiaxin L; Peiyun Z; Zheng T; Wei Y; Shanshan S; Lei R; Zhengwen X; Yong F; Xiaodong G; Anwei X; Kuntang S; Yingyong H
Aging (Albany NY); 2020 Jun; 12(12):11416-11430. PubMed ID: 32561689
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
17. Validation of the MSKCC Gastrointestinal Stromal Tumor Nomogram and Comparison with Other Prognostication Systems: Single-Institution Experience with 289 Patients.
Chok AY; Goh BK; Koh YX; Lye WK; Allen JC; Quek R; Teo MC; Chow PK; Ong HS; Chung AY; Wong WK
Ann Surg Oncol; 2015 Oct; 22(11):3597-605. PubMed ID: 25652053
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
19. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Vincenzi B; Napolitano A; Fiocco M; Mir O; Rutkowski P; Blay JY; Reichardt P; Joensuu H; Fumagalli E; Gennatas S; Hindi N; Nannini M; Spalato Ceruso M; Italiano A; Grignani G; Brunello A; Gasperoni S; De Pas T; Badalamenti G; Pantaleo MA; van Houdt WJ; IJzerman NS; Steeghs N; Gelderblom H; Desar IME; Falkenhorst J; Silletta M; Sbaraglia M; Tonini G; Martin-Broto J; Hohenberger P; Le Cesne A; Jones RL; Dei Tos AP; Gronchi A; Bauer S; Casali PG
Clin Cancer Res; 2022 Apr; 28(8):1672-1679. PubMed ID: 34615721
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts.
Lin Y; Wang M; Jia J; Wan W; Wang T; Yang W; Li C; Chen X; Cao H; Zhang P; Tao K
EBioMedicine; 2020 Oct; 60():103016. PubMed ID: 32980695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
